Tag Archives: clinical trial

Scrubbed Trial May Not Be the End for Mesothelioma Drug

The makers of the once-promising experimental mesothelioma drug defactinib have announced that they will stop a clinical trial of the drug early because, by itself, it does not appear to help. But this may not be the end of the road for defactinib in mesothelioma treatment. Defactinib (VS-6063) had been the leading compound for its manufacturer, Boston-based Verastem. While standard mesothelioma chemotherapy drugs like pemetrexed, cisplatin, gemcitabine and vinorelbine can sometimes shrink mesothelioma tumors, they also increase the percentage of stem cells which can give rise to new cancer. Defactinib was designed to help keep malignant mesothelioma patients from relapsing by inhibiting a crucial signaling pathway (FAK) inside the stem cells. Early studies were encouraging, but a recent review of … Continue reading Scrubbed Trial May Not Be the End for Mesothelioma Drug »

Clinical Trial May be Best Second-Line Approach for Mesothelioma

Doctor holding x-ray film

The best second-line treatment for mesothelioma patients who fail to respond to standard chemotherapy is probably to enroll in a clinical trial. The authors of a newly-published paper on the subject reached that conclusion after reviewing the results of 29 studies on potential second- or third-line mesothelioma treatments. Most patients who are diagnosed with mesothelioma, an aggressive malignancy associated with asbestos exposure, will undergo chemotherapy, either as a stand-alone treatment or as part of a multimodal approach. Unfortunately, only a small percentage of mesothelioma patients treated with standard pemetrexed/cisplatin chemotherapy will show a response. Even those who respond to chemotherapy often relapse again later. Scientists around the world are searching for new drugs and drug combinations to offer mesothelioma patients … Continue reading Clinical Trial May be Best Second-Line Approach for Mesothelioma »

Mesothelioma Report Suggests Clinical Trials Better Than Surgery

patient in bed

Doctors in the Department of Respiratory medicine at York Teaching Hospital in the UK are taking a hard stance against the surgical treatment of malignant pleural mesothelioma. In a recent article in the journal Thorax, the group contends that the research surrounding mesothelioma surgery is largely flawed and that the majority of mesothelioma patients would be better served if their doctors suggested alternatives. “Belief that the modest survival times reported after radical surgery, whether alone or as part of multimodal therapy, are longer than they would have been without surgery relies on data from highly selected, uncontrolled, retrospectively analyzed case series,” they write. They point out that the only randomized study, the Mesothelioma and Radical Surgery (MARS) trial showed no measurable … Continue reading Mesothelioma Report Suggests Clinical Trials Better Than Surgery »